U.S. markets closed

Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?

Zacks Equity Research

We expect investors to focus on Vaxart, Inc.’s VXRT development plans for its oral coronavirus vaccine candidates when it reports first-quarter 2020 earnings results.

Shares of Vaxart have skyrocketed 850.1% so far this year against the industry’s decline of 9.4%.


The stock price has been appreciating of late owing to the company’s recent progress in making efforts to fight the COVID–19 pandemic and develop a vaccine for the same.

Vaxart’s portfolio is currently devoid of any approved product. As a result, the company only generates revenues from royalty sales. Earlier this week, Vaxart announced that itwill receive $2.8 million in royalty revenues for the first quarter.

Recent Developments

Vaxart is looking to develop a vaccine candidate that can generate mucosal immune responses in addition to serum antibody responses, which are potentially significant for protection against the deadly COVID-19 infection. In April 2020, Vaxart announced positive data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19.

The study and development activities conducted in the March quarter in relation to the oral vaccine candidates are likely to have escalated the company’s operating expense in the period.

Notably, Vaxart has a manufacturing agreement with Emergent BioSolutions EBS wherein the latter will produce the clinical material for the company’s experimental oral vaccine candidates against COVID-19.

Emergent plans to produce bulk cGMP vaccine to help Vaxart begin a phase I clinical study in the second half of 2020.

Vaxart, Inc. Price and EPS Surprise

VAXART, INC. Price and EPS Surprise

Vaxart, Inc. price-eps-surprise | Vaxart, Inc. Quote

Zacks Rank & Other Stocks to Consider

Vaxart currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the biotech sector include Adamis Pharmaceuticals Corporation ADMP and Avenue Therapeutics, Inc. ATXI, both sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Adamis Pharmaceuticals’ loss per share estimates have been narrowed 10.5% for 2020 and 8.3% for 2021 over the past 60 days.

Avenue Therapeutics’ loss per share estimates have been narrowed 28.6% for 2020 and 26% for 2021 over the past 60 days.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
Adamis Pharmaceuticals Corporation (ADMP) : Free Stock Analysis Report
 
Avenue Therapeutics, Inc. (ATXI) : Free Stock Analysis Report
 
VAXART, INC. (VXRT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research